MAR 03, 2018 12:58 AM PST

Doubting the Wonder Drug

WRITTEN BY: Nouran Amin

Baclofen is a drug used to treat an alcohol use disorder. It has long been debuted as the "Wonder Drug" for several of its unique characteristics. For one, baclofen is secreted from the kidneys, not the liver which is particularly advantageous to individuals suffering from liver disease due to an alcohol use disorder (AUD).


Image: University of Liverpool via TechExplorist.com

Historically, baclofen was developed by Dr. Heinrich Keberle in 1962 initially to treat epilepsy. But because of its muscle relaxant properties, it was used instead for the treatment of spasticity particularly in cases related to multiple sclerosis. It was also used in spinal cord injuries for painful muscle spasms.

So, what is baclofen? Baclofen is a GABA receptor agonist that works to suppress the nervous system from an overdose. It's hypothesized that individuals with an AUD are GABA receptor-deficient and thus taking baclofen may reverse this complication and reduce alcohol dependence.

Image Source: ArcaGeorgia.com

However, the mechanism of action of baclofen particularly in treating AUD, still remains unknown. Such mystery encouraged researchers at the University of Liverpool to re-examine the wonder drug.

Originally, the support of baclofen in treating AUD comes from clinical studies showing a decrease in mood swings, depression, and anxiety. Participants also experienced a reduction in alcohol craving.

Now, addiction researchers at the University of Liverpool are questioning the effectiveness of baclofen. Lead researchers, Dr. Abi Rose and Dr. Andy Jones performed a meta-analysis study of roughly 12 clinical trials to see if baclofen holds true in treating alcohol dependence. The purpose was to re-examine the original clinical study that showed support for baclofen and to compare this study across various variables including the placement of a placebo. The meta-analysis study merged all results together to ensure accuracy and reliability of the effectiveness of baclofen.

The addiction research team found that alcohol dependence was reduced in comparison to a placebo. However, that was not sufficient enough as baclofen did not increase alcohol abstinence over a period of days. It was also found that it did not decrease alcohol craving, anxiety, or depression.

Even though the outcomes of this study were more accurate in comparison to the original clinical trial, there are still issues that need to be examined in these current clinical trials. Dr. Rose of the addiction team states, "The existing trials also differ on a number of factors, such as the dose of baclofen given and the length of treatment. Importantly, the pharmacokinetics of baclofen (how it moves in the body) are not well-understood, so there may be individual factors influencing the effectiveness of baclofen that we do not yet understand." The research claims that the use of baclofen in the treatment of an AUD is ‘premature’.

The results of this study were published in the Addiction journal.

Sources: Science Daily, Addiction

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Treating Malaria: Molecular Understanding of Drug Interactions
Crystallization is a process central to drug development that despite centuries of facilitating a particular method, chemists are still learning how to gra...
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
Taking Psychedelics Improves Mood, says Yale Researchers
Psychedelics have long been known for their potential to enable deep reflection and modulate people’s moods. But evidence for this mostly came from a...
JAN 21, 2020
Drug Discovery & Development
JAN 21, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
FEB 10, 2020
Drug Discovery & Development
FEB 10, 2020
Drug Prevents Coronavirus in Monkeys
An antiviral drug successfully prevented Middle East respiratory syndrome coronavirus (MERS-CoV) in infected rhesus macaques. The drug, Remdesivir, was adm...
MAR 13, 2020
Immunology
MAR 13, 2020
Malaria drug treats lupus and prevents diabetes
A drug commonly used to treat certain types of malaria has been found to have some surprising synergistic effects: having an anti-inflammatory effect on lu...
Loading Comments...